• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人血浆血小板活化因子乙酰水解酶。纯化及性质

Human plasma platelet-activating factor acetylhydrolase. Purification and properties.

作者信息

Stafforini D M, Prescott S M, McIntyre T M

出版信息

J Biol Chem. 1987 Mar 25;262(9):4223-30.

PMID:3558407
Abstract

Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a biologically active phospholipid synthesized by a variety of cell types upon appropriate stimulation. PAF is a potent hypotensive factor and it activates platelets and inflammatory cells at concentrations as low as 10(-10) M. Removal of the acetyl moiety at the sn-2 position abolishes the biological activity and this reaction is catalyzed by a specific acetylhydrolase present in plasma and animal tissues. Ultracentrifugation in density gradients showed that 30% of the activity is associated with high density lipoproteins and 70% with low density lipoproteins. We have purified the plasma low density lipoprotein-associated activity to near homogeneity using a rapid assay based on the separation of [3H]acetate from 1-O-alkyl-2-[3H]acetyl-sn-glycerol-3-phosphocholine on disposable reversed-phase columns. The enzyme was purified by 25,000-fold and approximately 10% of the starting activity was recovered. Plasma PAF-acetylhydrolase has an apparent molecular weight of 43,000, does not require calcium, has preference for micellar versus monomeric substrate, and exhibits surface dilution kinetics. The purified protein has an apparent Km of 13.7 microM and a Vmax of 568 mumol/h/mg with micellar PAF. It can act both on 1-O-alkyl and 1-acyl substrates and on ethanolamine analogs of PAF. However, the enzyme has a marked preference for the sn-2 acetyl residue and therefore can be considered as a specific PAF-acetylhydrolase.

摘要

血小板活化因子(PAF,1-O-烷基-2-乙酰基-sn-甘油-3-磷酸胆碱)是一种生物活性磷脂,在适当刺激下由多种细胞类型合成。PAF是一种强效降压因子,在低至10^(-10) M的浓度下就能激活血小板和炎症细胞。去除sn-2位的乙酰基部分会消除其生物活性,而该反应由血浆和动物组织中存在的一种特异性乙酰水解酶催化。密度梯度超速离心显示,30%的活性与高密度脂蛋白相关,70%与低密度脂蛋白相关。我们使用一种基于在一次性反相柱上从1-O-烷基-2-[3H]乙酰基-sn-甘油-3-磷酸胆碱中分离[3H]乙酸盐的快速测定法,将血浆低密度脂蛋白相关活性纯化至接近均一。该酶被纯化了25000倍,回收了约10%的起始活性。血浆PAF-乙酰水解酶的表观分子量为43000,不需要钙,对胶束状底物比对单体底物更具偏好性,并表现出表面稀释动力学。纯化后的蛋白质对胶束状PAF的表观Km为13.7 microM,Vmax为568 mumol/h/mg。它既能作用于1-O-烷基和1-酰基底物,也能作用于PAF的乙醇胺类似物。然而,该酶对sn-2乙酰基残基有明显偏好,因此可被视为一种特异性PAF-乙酰水解酶。

相似文献

1
Human plasma platelet-activating factor acetylhydrolase. Purification and properties.人血浆血小板活化因子乙酰水解酶。纯化及性质
J Biol Chem. 1987 Mar 25;262(9):4223-30.
2
Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.人血浆血小板活化因子乙酰水解酶。与脂蛋白颗粒的关联及在血小板活化因子降解中的作用。
J Biol Chem. 1987 Mar 25;262(9):4215-22.
3
Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein.人血浆低密度脂蛋白中的血小板活化因子乙酰水解酶和转乙酰酶活性
Biochem J. 2001 Jul 15;357(Pt 2):457-64. doi: 10.1042/0264-6021:3570457.
4
An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma.磷脂酰胆碱的一种氧化衍生物是人血浆中血小板活化因子乙酰水解酶的底物。
J Biol Chem. 1989 Apr 5;264(10):5331-4.
5
The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease).
Blood. 1985 Dec;66(6):1476-8.
6
Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.脂蛋白改变人血浆中血小板活化因子乙酰水解酶的催化行为。
Proc Natl Acad Sci U S A. 1989 Apr;86(7):2393-7. doi: 10.1073/pnas.86.7.2393.
7
Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase.肝细胞分泌血小板活化因子乙酰水解酶的血浆形式。
J Biol Chem. 1991 Sep 5;266(25):16667-73.
8
Release of platelet-activating factor in systemic lupus erythematosus.系统性红斑狼疮中血小板活化因子的释放
Int Arch Allergy Appl Immunol. 1990;91(3):244-56. doi: 10.1159/000235124.
9
Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme.血小板活化因子乙酰水解酶:广泛的底物特异性和脂蛋白结合并不调节血浆酶的催化特性。
Biochemistry. 2001 Apr 17;40(15):4539-49. doi: 10.1021/bi002600g.
10
Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility.人血浆低密度脂蛋白中血小板活化因子乙酰水解酶的可解离和不可解离形式:对低密度脂蛋白氧化易感性的影响
Biochim Biophys Acta. 1999 Jan 29;1437(1):23-36. doi: 10.1016/s0005-2760(98)00177-5.

引用本文的文献

1
Associations between healthy food groups and platelet-activating factor, lipoprotein-associated phospholipase A and C-reactive protein: a cross-sectional study.健康食物组与血小板激活因子、脂蛋白相关磷脂酶 A 和 C 反应蛋白之间的关联:一项横断面研究。
Eur J Nutr. 2024 Mar;63(2):445-460. doi: 10.1007/s00394-023-03277-8. Epub 2023 Dec 8.
2
Switching the substrate specificity of lysoplasmalogen-specific phospholipase D.切换溶酶体磷脂酶 D 对赖氨酸质体的特异性。
FEBS Open Bio. 2021 Apr;11(4):1132-1143. doi: 10.1002/2211-5463.13123. Epub 2021 Mar 19.
3
Lipopolysaccharide Cross-Tolerance Delays Platelet-Activating Factor-Induced Sudden Death in Swiss Albino Mice: Involvement of Cyclooxygenase in Cross-Tolerance.
脂多糖交叉耐受性延迟血小板活化因子诱导的瑞士白化小鼠猝死:环氧化酶在交叉耐受性中的作用。
PLoS One. 2016 Apr 11;11(4):e0153282. doi: 10.1371/journal.pone.0153282. eCollection 2016.
4
New and emerging biomarkers in cardiovascular disease.心血管疾病中的新型和新兴生物标志物。
Curr Diab Rep. 2015 Nov;15(11):88. doi: 10.1007/s11892-015-0661-y.
5
Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFκB pathways.载脂蛋白CIII通过丝裂原活化蛋白激酶(MAPK)和核因子κB(NFκB)信号通路调节脂蛋白相关磷脂酶A2的表达。
Biol Open. 2015 Apr 2;4(5):661-5. doi: 10.1242/bio.201410900.
6
Novel metabolic biomarkers of cardiovascular disease.心血管疾病的新型代谢生物标志物。
Nat Rev Endocrinol. 2014 Nov;10(11):659-72. doi: 10.1038/nrendo.2014.155. Epub 2014 Sep 2.
7
In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.两种一线抗逆转录病毒疗法方案对男性 HIV 患者炎症介质的体内影响。
Lipids Health Dis. 2014 May 29;13:90. doi: 10.1186/1476-511X-13-90.
8
Time course-changes in phosphatidylcholine profile during oxidative modification of low-density lipoprotein.时间进程-在低密度脂蛋白氧化修饰过程中磷脂酰胆碱谱的变化。
Lipids Health Dis. 2014 Mar 14;13:48. doi: 10.1186/1476-511X-13-48.
9
Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials.脂蛋白相关磷脂酶 A₂ 抑制对血小板聚集无影响:来自体外研究和两项随机 I 期临床试验的结果。
PLoS One. 2014 Jan 27;9(1):e83094. doi: 10.1371/journal.pone.0083094. eCollection 2014.
10
Bacterial clearance is improved in septic mice by platelet-activating factor-acetylhydrolase (PAF-AH) administration.血小板激活因子乙酰水解酶(PAF-AH)给药可改善脓毒症小鼠的细菌清除率。
PLoS One. 2013 Sep 12;8(9):e74567. doi: 10.1371/journal.pone.0074567. eCollection 2013.